Key Points
- CFO Daniel Lochner bought 6,000 shares on Feb. 10 at $21.61 each for a total of $129,660, raising his direct stake to 32,044 shares — a 23.04% increase in his ownership.
- Tectonic shares opened at $22.01 (up 4.6%), trade near a 50-day/200-day moving average of $20.51/$19.64, and the company has a market cap of about $412.0 million with a 52-week range of $13.70–$36.11.
- The stock carries a consensus rating of “Moderate Buy” with an average target of $81.50, reflecting mixed analyst views (one Strong Buy, five Buy, one Sell), while institutional investors own about 62.63% and some funds recently increased sizable positions.
Tectonic Therapeutic, Inc. (NASDAQ:TECX - Get Free Report) CFO Daniel Lochner acquired 6,000 shares of the business's stock in a transaction dated Tuesday, February 10th. The shares were bought at an average cost of $21.61 per share, for a total transaction of $129,660.00. Following the transaction, the chief financial officer directly owned 32,044 shares in the company, valued at approximately $692,470.84. This represents a 23.04% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Tectonic Therapeutic Stock Up 4.6%
Shares of Tectonic Therapeutic stock opened at $22.01 on Thursday. The business has a 50 day moving average price of $20.51 and a 200-day moving average price of $19.64. Tectonic Therapeutic, Inc. has a 52 week low of $13.70 and a 52 week high of $36.11. The company has a market cap of $412.03 million, a PE ratio of -5.70 and a beta of 3.71.
Wall Street Analyst Weigh In
TECX has been the subject of a number of research reports. Wells Fargo & Company began coverage on shares of Tectonic Therapeutic in a research report on Monday, October 20th. They set an "overweight" rating and a $101.00 target price for the company. Truist Financial lowered their target price on Tectonic Therapeutic from $64.00 to $60.00 and set a "buy" rating on the stock in a research note on Thursday, January 8th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Tectonic Therapeutic in a research note on Thursday, January 22nd. Finally, Lifesci Capital upgraded Tectonic Therapeutic to a "strong-buy" rating in a research note on Thursday, February 5th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $81.50.
Check Out Our Latest Analysis on TECX
Institutional Trading of Tectonic Therapeutic
Hedge funds have recently bought and sold shares of the company. Aberdeen Group plc increased its position in shares of Tectonic Therapeutic by 220.6% in the fourth quarter. Aberdeen Group plc now owns 1,141,824 shares of the company's stock valued at $23,818,000 after acquiring an additional 785,648 shares during the period. Braidwell LP bought a new stake in shares of Tectonic Therapeutic in the third quarter worth about $11,561,000. Millennium Management LLC grew its stake in shares of Tectonic Therapeutic by 726.4% in the first quarter. Millennium Management LLC now owns 237,938 shares of the company's stock worth $4,214,000 after purchasing an additional 209,145 shares during the last quarter. Kennedy Capital Management LLC purchased a new position in Tectonic Therapeutic during the 3rd quarter valued at about $3,276,000. Finally, First Light Asset Management LLC bought a new position in Tectonic Therapeutic during the 3rd quarter valued at approximately $3,176,000. Institutional investors own 62.63% of the company's stock.
Tectonic Therapeutic Company Profile
(
Get Free Report)
Tectonic Therapeutic, Inc engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
